OJNeph  Vol.4 No.1 , March 2014
Before the Jury Is out on Cinacalcet’s Cardiovascular Effects in Hemodialysis Patients: Is Troponin a Missing Link?
Abstract: Raised levels of the cardiac biomarker, Troponin I, are frequently encountered in hemodialysis patients and appear to be prognostic indicators for cardiovascular risk. Though evidence suggests that control of secondary hyperparathyroidism may reduce cardiac endpoints, the effect of the calcimimetic agent, cinacalcet, remains controversial. This retrospective study aimed at evaluating troponin levels in hemodialysis patients with severe secondary hyper parathyroidism (SHPT) who are on cinacalcet vs controls on conventional treatment. In addition, clinical outcomes including all-cause, cardiovascular morbidity and mortality were compared among both groups. A decline in Troponin I levels was observed in the cinacalcet group, this however was not translated clinically into improved survival. In fact, all-cause and cardiac mortality was similar in the two groups. Conversely, comparison of the incidence of cardiovascular events revealed lower rates in the cinacalcet group including cardiac, cerebral and peripheral vascular complications. Given some of our study limitations, further long-term, placebo-controlled trials are necessary to definitively establish the effect of cinacalet on cardiac biomarkers and ultimately its impact on clinical outcomes.
Cite this paper: S. Abouchacra, A. Chaaban, M. Budruddin, F. Chedid, M. Hakim, M. Ahmed, N. Gebran, F. Marzouki, M. Hassan and F. Abbacheyi, "Before the Jury Is out on Cinacalcet’s Cardiovascular Effects in Hemodialysis Patients: Is Troponin a Missing Link?," Open Journal of Nephrology, Vol. 4 No. 1, 2014, pp. 47-53. doi: 10.4236/ojneph.2014.41007.

[1]   Salgueira, M., del Toro, N., Moreno-Alba, R., Jimenez, E., Areste, N., et al. (2003) Vascular Calcification in the Uremic Patient: A Cardiovascular Risk? Kidney International, Supl, S119-S121.

[2]   Costa-Hong, V., Jorgetti, V., Gowdak, L.H., Moyses, R.M., Krieger, E.M. and De Lima, J.J. (2007) Parathyroidectomy Reduces the Cardiovascular Events and Mortality in Renal Hyperparathyroidism. Surgery, 142, 699-703.

[3]   Block, G.A., Zaun, D., Smits, G., Persky, M., Brillhart, S., et al. (2010) Cinacalcet Hydrochloride TNT Significantly Improves All Cause and Cardiovascular Survival in a Large Cohort of Hemodialysis Patients. Kidney International, 78, 578-599.

[4]   Gaiki, M.R., Devita, M.V., Michelis, M.F., Panagopoulos, G. and Rosenstock, J.L. (2012) Troponin I as a Prognostic Marker of Cardiac Events in Symptomatic Hemodialysis Patients Using a Sensitive Trop I Assay. International Urology and Nephrology, 44, 1841-1845.

[5]   Artunc, F., Mueller, C., Breidthardt, T., Twerenbold, R., Peter, A., Thamer, C., Weyrich, P., Haering, H.U. and Friedrich, B. (2012) Sensitive Troponins Which Suits Better for Hemodialysis Patients? Associated Factors and Prediction of Mortality. PLOS One, 7, Article ID: e47610.

[6]   Flisinski, M., Strozecki, P., Stefanska, A., Zarzycka-Lindner, G., Brymora, A. and Manitius, J. (2007) Cardiac Troponin I in Patients with Chronic Kidney Disease Treated Conservatively or Undergoing Long-Term Haemodialysis. Kardiologia Polska, 65, 1068-1078.

[7]   Kalaji, F.R. and Albitar, S. (2012) Predictive Value of Cardiac Troponin T and I in Hemodialysis Patients. Saudi Journal of Kidney Disease and Transplantation, 23, 939-945.

[8]   Geerse, D.A., Van Berkel, M., Vogels, S., Kooman, J.P., Konings, C.J. and Scharnhorst, V. (2012) Moderate Elevation of High Sensitivity Cardiac Troponin I and B Type Natriuretic Peptide in Chronic Hemodialysis Patients Are Associated with Mortality. Clinical Chemistry and Laboratory Medicine, 10, 1-8.

[9]   Hagstrom, E., Hellman, P., Larsson, T.E., Ingelsso, E., Berglund, L., Sundstrom, J., Meihus, H., Held, C., Lind, L., Michaelsson, K. and Aenlov, J. (2009) Plasma Parathyroid Hormone and the Risk of Cardiovascular Mortality in the Community. Circulation, 119, 2765-2771.

[10]   Weiner, D.E., Tabatabai, S., Tighiouart, H., Elsayed, E., Bansal, N., et al. (2006) Cardiovascular Outcomes and All-Cause Mortality: Exploring the Interaction between CKD and Cardiovascular Disease. American Journal of Kidney Diseases, 48, 392-401.

[11]   Shantouf, R., Kovesdy, C.P., Kim, Y., Ahmadi, N., Luna, A., Luna, C., Rambod, M., Nissenson, A.R., Budoff, M.J. and Kalantar-Zadeh, K. (2009) Association of Serum Alkaline Phosphatise with Coronary Artery Calcification in Maintenance Hemodialysis Patients. Clinical Journal of the American Society of Nephrology, 6, 1106-1114.

[12]   Zhang, Q., Li, M., You, L., Li, H.M., Ni, L., Gu, Y., Hao, C.M. and Chen, J. (2012) Effects and Safety of Calcimimetics in End Stage Renal Disease Patients with Secondary Hyperparathyroidism: A Meta-Analysis. PLoS One, 7, Article ID: e48070.

[13]   Block, G.A., Martin, K.J., de Francisco, A.L., Turner, S.A., Avram, M.M., et al. (2004) Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis. The New England Journal of Medicine, 350, 1516-1525.

[14]   Fukagawa, M., Yumita, S., Akizawa, T., Uchida, E., Tsukamoto, Y., et al. (2008) Cinacalcet (KRN1493) Effectively Decreases the Serum Intact PTH Level with Favourable Control of the Serum Phosphorous and Calcium Levels in Japanese Dialysis Patients. Nephrology Dialysis Transplantation, 23, 328-335.

[15]   Saleh, F.N., Schirmer, H., Sundsfjord, J. and Jorde, R. (2003) Parathyroid Hormone and Left Ventricular Hypertrophy. European Heart Journal, 24, 2054-2060.

[16]   Johnson, D.W., Craven, A.M. and Isbel, N.M. (2007) Modification of Cardiovascular Risk in Hemodialysis Patients: An Evidence-Based Review. Hemodialysis International, 11, 1-14.

[17]   Goodman, W.G., Goldin, J., Kuizon, B.D., Yoon, C., Gales, B., et al. (2000) Coronary Artery Calcification in Young Adults with End Stage Renal Disease Who Are Undergoing Dialysis. The New England Journal of Medicine, 342, 1478-1483.

[18]   Andersson, P., Rydberg, E. and Willenheimer, R. (2004) Primary Hyperparathyroidism and Heart Disease: A Review. European Heart Journal, 25, 1776-1787.

[19]   Giovannucci, E., Liu, Y., Hollis, B.W. and Rimm, E.B. (2008) 25-Hydroxyvitamin D and Risk of Myocardial Infarction in Men: A Prospective Study. Archives of Internal Medicine, 168, 1174-1180.

[20]   Wolfe, R.H., Ashby, V.B., Milford, E.L., Ojo, A.O., Ettenger, R.E., Agodoa, L.Y., Held, P.J. and Port, F.K. (1999) Comparison of Mortality in all Patients on Dialysis, Patients on Dialysis Awaiting Transplantation and Recipients of a First Cadaveric Transplant. The New England Journal of Medicine, 341, 1725-1730.

[21]   Cunninghm, J., Danese, M., Olson, K., Klassen, P. and Chertow, G.M. (2005) Effects of the Calcimimetic Cinacalcet HCl on Cardiovascular Disease, Fracture, and Health Related Quality of Life in Secondary Hyperparathyroidism. Kidney International, 68, 1793-1800.

[22]   Raggi, P., Chertow, G.M., Torres, P.U., Csiky, B., Naso, A., et al. (2011) The ADVANCE Study: A Randomised Study to Evaluate the Effects of Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Patients on Hemodialysis. Nephrology Dialysis Transplantation, 26, 1327-1339.

[23]   Palmer, S.C., Nistor, I., Craig, J.C., Pellegrini, F., Messa, P., Tonelli, M., Covic, A. and Strippoli, G.F.M. (2013) Cinacalcet in Patients with Chronic Kidney Disease: A Cumulative Meta-Analysis of Randomised Controlled Trials. PLOS Medicine, 10, Article ID: e1001436.

[24]   Glenn, M.C., Geoffrey, A.B., Ricardo, C.R., Tilman, B.D., Jurgen, F., willim, G.G., Charles, A.H., Yumi, K., Gerard, M.L., Kenneth, W.M., Christian, T.H., Sharon, M.M., Marie, L.T., David, C.W. and Patrick, S.P. (2012) Evaluation of Cinacalcet Hydrochloride Therapy to Lower Cardio Vascular Events. The New England Journal of Medicine, 2, 898-905.

[25]   The Evolve Trial Investigators (2012) Effects of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis. The New England Journal of Medicine, 367, 2482-2494.

[26]   Lee, C.T., Tsai, Y.C., Ng, H.Y., Su, Y., Lee, W.C., Lee, L.C., Chiou, T.T., Liao, S.C. and Hsu, K.T. (2009) Association between C-Reactive Protein and Biomarkers of Bone and Mineral Metabolism in Chronic Hemodialysis Patients: A Cross-Sectional Study. Journal of Renal Nutrition, 19, 220-227.